Merck & Co. has begun constructing an additional facility at its Carlow, Ireland site to meet demand for its medicines and vaccines. Merck & Co. (known as MSD outside North America) says that construction of a new facility at its existing site in Carlow, Ireland – about 80km south-west of Dublin – will focus specifically on manufacturing next generation oncology biologics. “The demand for MSD’s range of vaccine and biologics products has continued to grow since 2008 and this new…
Cytiva’s support will enable Caring Cross to develop and distribute its CAR-T cell therapy for HIV to low-to-middle-income countries, says firm. Caring Cross’ first therapeutic candidate is an anti-HIV duoCAR-T cell therapy, which the organization claims is designed to supress HIV replication and remove HIV-expressing cells in individuals with HIV. Additionally, it is developing a stem cell gene therapy for sickle cell disease and beta-thalassemia. “Approximately 38 million people worldwide are living with HIV. Current treatment options are limited to…